Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | CALML3 | P27482 | 7/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703133 | 0.87 | MAOA (0.53) | MAOACALML3F10MAOB | |
| SCHEMBL5762110 | 0.84 | MAOA (0.61) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL5763630 | 0.84 | MAOA (0.48) | MAOACALML3F10MAOB | |
| SCHEMBL5763819 | 0.82 | MAOB (0.51) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL5763175 | 0.82 | MAOB (0.46) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL5739005 | 0.81 | MAOA (0.56) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL4014717 | 0.80 | MAOA (0.53) | MAOACALML3F10MAOB | |
| SCHEMBL6164483 | 0.79 | MAOA (0.52) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL6161576 | 0.79 | MAOA (0.57) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL6161767 | 0.79 | MAOA (0.52) | MAOACALML3F10MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094900-B2 | N-Aryl-2-oxazolidinones and their derivatives | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1539745-B1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | GADWOOD ROBERT C (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | OXA1L, NDUFS7, NDUFS6 | MAOA 854/4885CALML3 4503/4885F10 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.